Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07213804CT.gov A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | — | Recruiting | — | — | — |
NCT05605535CT.gov Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04807166CT.gov Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | — | Active Not Recruiting | — | — | — |
NCT04498117CT.gov Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | — | Active Not Recruiting | — | — | — |
NCT02658214CT.gov Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT01478685CT.gov A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
NCT01279291CT.gov Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | — | Terminated | — | — | — |
NCT00698451CT.gov A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | — | Completed | — | — | — |
NCT00407407CT.gov ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma | — | Terminated | — | — | — |
NCT00391118CT.gov Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT00063401CT.gov Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | — | Completed | — | — | — |
NCT00112086CT.gov OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 | — | Completed | — | — | — |
NCT00006155CT.gov SU5416 and Carboplatin to Treat Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Eli Lilly and Company | P3 | BB · 70 |
| Adriamycin | Eli Lilly and Company | P3 | BB |
| Nogitecan | Eli Lilly and Company | P3 | B |
| Mirvetuximab Soravtansine | Eli Lilly and Company | P3 | B |
| Sofetabart Mipitecan | Eli Lilly and Company | P3 | B |
| Trabectedin | Janssen Research & Development, LLC | P3 | B |
| Pembrolizumab | Seagen, a wholly owned subsidiary of Pfizer | P3 | B |
| Dexasone | Janssen Research & Development, LLC | P3 | B |
| Letrozole | Swiss GO Trial Group | P3 | B |
+31 more in the Fallopian Tube Neoplasm cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Fallopian Tube Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-fallopian-tube-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →